Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.40 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 3/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480501 | 0.81 | MAPT (0.48) | MAPT | |
| SCHEMBL3920516 | 0.79 | CNR2 (0.36) | BCL2BCL2L1MCL1P2RY14 | |
| SCHEMBL3480342 | 0.79 | SNCA (0.46) | SNCAMAPTHSD17B1HSD17B2PKLR | |
| SCHEMBL3480451 | 0.78 | ATIC (0.46) | P2RY14POLB | |
| SCHEMBL3480263 | 0.77 | MAPT (0.34) | MAPTP2RY14 | |
| SCHEMBL16667405 | 0.76 | P2RY14 (0.38) | MAPTP2RY14 | |
| SCHEMBL3480445 | 0.76 | SERPINE1 (0.38) | — | |
| SCHEMBL3480434 | 0.75 | MMP13 (0.45) | POLB | |
| SCHEMBL3480234 | 0.74 | SNCA (0.63) | SNCAMAPTHSD17B1HSD17B2ESR1 | |
| SCHEMBL4427998 | 0.72 | SMN1; SMN2 (0.55) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | claimed |
| EP-2024376-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007139729-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2007-12-06 | — | — | WO | claimed |
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | disclosed |
| EP-2024376-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007139729-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MGAM, BPGM, PPME1 | SNCA 2555/4885MAPT 4576/4885HSD17B1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.